Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986183 in Advanced Hepatocellular Carcinoma
NCT02828124Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of BMS-986183 in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Aug 2016; status: terminated.
02
Drugs
BMS-986183
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02828124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828124.